Literature DB >> 29854391

Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence.

Matthew P Rochester1, Allison M Kane1, Sunny Anne Linnebur2, Danielle R Fixen3.   

Abstract

Antidepressants are widely used medications for a range of medical conditions such as mood disorders and chronic pain in older adults. A vast body of evidence exists concerning the risks of QT interval prolongation associated with these agents and healthcare providers should critically evaluate the potential for QT prolongation when selecting antidepressant agents. Long QT syndrome is a disorder of myocardial repolarization that manifests as a prolonged QT interval on an electrocardiogram (ECG) and has been demonstrated to increase with age. The objective of this review is to present and evaluate existing literature regarding the risk of QT prolongation in older adults, age 60 years and older, and discuss the implications for clinical practice. A PubMed search was conducted to identify studies evaluating the QT prolonging effects of antidepressant medications and publications were chosen based on pertinent criteria. Depending on the antidepressant agent and patient-specific factors, clinicians should assess and monitor electrolytes and EGCs to evaluate the risks and benefits for older adults receiving agents known to prolong the QT interval.

Entities:  

Keywords:  QT prolongation; QTc interval; antidepressants; antidepressive agents; elderly; long QT syndrome; long QT syndrome/chemically induced; older adults

Year:  2018        PMID: 29854391      PMCID: PMC5971403          DOI: 10.1177/2042098618772979

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  31 in total

1.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

Review 2.  The QT interval: too long, too short or just right.

Authors:  Sami Viskin
Journal:  Heart Rhythm       Date:  2009-03-03       Impact factor: 6.343

3.  Datapoints: Prevalence of QT prolongation among veterans with severe mental illness.

Authors:  Eileen M Stock; Laurel A Copeland; Ruth L Bush; John E Zeber
Journal:  Psychiatr Serv       Date:  2013-10       Impact factor: 3.084

4.  Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.

Authors:  Nevena M Maljuric; Raymond Noordam; Nikkie Aarts; Maartje N Niemeijer; Marten E van den Berg; Albert Hofman; Jan A Kors; Bruno H Stricker; Loes E Visser
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

5.  Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey.

Authors:  Mark Hamer; G David Batty; G David Batty; Adrie Seldenrijk; Mika Kivimaki
Journal:  Eur Heart J       Date:  2010-11-30       Impact factor: 29.983

6.  Psychotropic drugs associated with corrected QT interval prolongation.

Authors:  Charlotte van Noord; Sabine M J M Straus; Miriam C J M Sturkenboom; Albert Hofman; Albert-Jan L H J Aarnoudse; Vincenzo Bagnardi; Jan A Kors; Christopher Newton-Cheh; Jacqueline C M Witteman; Bruno H C Stricker
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

Review 7.  Torsade de pointes.

Authors:  Nabil El-Sherif; Gioia Turitto
Journal:  Curr Opin Cardiol       Date:  2003-01       Impact factor: 2.161

8.  QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study.

Authors:  Ingrid M M van Haelst; Wilton A van Klei; Hieronymus J Doodeman; Miriam J Warnier; Marie L De Bruin; Cor J Kalkman; Toine C G Egberts
Journal:  J Clin Psychiatry       Date:  2014-01       Impact factor: 4.384

9.  Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010.

Authors:  Christoph Josef Spindelegger; Konstantinos Papageorgiou; Renate Grohmann; Rolf Engel; Waldemar Greil; Anastasios Konstantinidis; Marcus Willy Agelink; Stefan Bleich; Eckart Ruether; Sermin Toto; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

Authors:  Lea T Drye; David Spragg; D P Devanand; Constantine Frangakis; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Bruce G Pollock; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more
  11 in total

1.  Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant.

Authors:  Hung-Tsung Hsiao; Jeffrey Chi-Fei Wang; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2022-06-03

2.  A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults.

Authors:  Yara K Haddad; Ramakrishna Kakara; Zachary A Marcum
Journal:  J Am Geriatr Soc       Date:  2022-02-08       Impact factor: 7.538

Review 3.  Psychological and pharmacological interventions for depression in patients with coronary artery disease.

Authors:  Phillip J Tully; Ser Yee Ang; Emily Jl Lee; Eileen Bendig; Natalie Bauereiß; Jürgen Bengel; Harald Baumeister
Journal:  Cochrane Database Syst Rev       Date:  2021-12-15

Review 4.  Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

Authors:  Giovanni Ostuzzi; Davide Papola; Chiara Gastaldon; Georgios Schoretsanitis; Federico Bertolini; Francesco Amaddeo; Alessandro Cuomo; Robin Emsley; Andrea Fagiolini; Giuseppe Imperadore; Taishiro Kishimoto; Giulia Michencigh; Michela Nosé; Marianna Purgato; Serdar Dursun; Brendon Stubbs; David Taylor; Graham Thornicroft; Philip B Ward; Christoph Hiemke; Christoph U Correll; Corrado Barbui
Journal:  BMC Med       Date:  2020-07-15       Impact factor: 8.775

5.  The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.

Authors:  Koen G A M Hussaarts; Florine A Berger; Lisette Binkhorst; Esther Oomen-de Hoop; Roelof W F van Leeuwen; Robbert J van Alphen; Daniëlle Mathijssen-van Stein; Natasja M S de Groot; Ron H J Mathijssen; Teun van Gelder
Journal:  Pharm Res       Date:  2019-12-16       Impact factor: 4.200

6.  Therapeutic Dose of Amitriptyline for Older Patients with Burning Mouth Syndrome.

Authors:  Takayuki Suga; Miho Takenoshita; Takeshi Watanabe; Trang Th Tu; Lou Mikuzuki; Chaoli Hong; Kazuhito Miura; Tatsuya Yoshikawa; Takahiko Nagamine; Akira Toyofuku
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-30       Impact factor: 2.570

7.  Hydroxychloroquine and Potential Drug Interactions in Older Adults.

Authors:  Verónica Velasco-González; Ana Fernández-Araque; Maria Sainz-Gil; Natalia Jimeno; Luis H Martín; Zoraida Verde
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-10-01       Impact factor: 4.872

8.  Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence.

Authors:  Michael J Schuh; Sheena Crosby
Journal:  Innov Pharm       Date:  2020-04-30

9.  Screening for atrial fibrillation and other arrhythmias in primary care.

Authors:  Kam Cheong Wong; Cindy Kok; Simone Marschner; Tim Usherwood; Clara K Chow
Journal:  BMC Fam Pract       Date:  2020-05-06       Impact factor: 2.497

10.  Hydroxychloroquine and Potential Drug Interactions in Older Adults.

Authors:  Verónica Velasco-González; Ana Fernández-Araque; Maria Sainz-Gil; Natalia Jimeno; Luis H Martín; Zoraida Verde
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-07-14       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.